Center of Excellence
Leaders in the field sharing authoritative insights and institutional best practices.
In this podcast, Jonathan Meyer, MD, discusses the role of D2 antagonism in schizophrenia treatment, lessons learned about schizophrenia treatment from clozapine, and emerging treatments for schizophrenia and their therapeutic targets.
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
In this video, Christoph U. Correll, MD, discusses additional research needed on the combination of olanzapine and the mu-opioid antagonist samidorphan.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
YOUR QUESTIONS ANSWERED
Does seeing a patient via telepsychiatry complicate the Abnormal Involuntary Movement Scale (AIMS) exam? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.
Did you enjoy reading the Schizophrenia Center of Excellence Compendium? Let us know what you liked best and what you would like to see in future coverage.
In a study incorporating genetic data from more than 125,000 people, researchers have implicated 10 new genes in the development of schizophrenia.
Researcher Christian Hakulinen, PhD, shares details of a study which found that higher amounts of time spent in a low-income environment during childhood were associated with increased risk of schizophrenia after age 15.
Sophia Frangou, MD, PhD, FRCPsych, discusses a study that suggests people with schizophrenia develop the vulnerability to hear “voices” years before the onset of symptoms.
Researcher Michael Birnbaum, MD, discusses a recent study which found significant trends in the Facebook activity of young people in the month before the onset of psychosis.